title: [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
abstract: OBJECTIVE
  Many studies on infliximab have confirmed its efficacy in the remission induction and even maintenance in refractory and fistulizing Crohn's disease. We report the treatment efficacy of infliximab in Crohn's disease and ulcerative colitis refractory to steroid treatment and the complications of infliximab treatment.
  
  
  METHODS
  We performed infliximab administration in 5 cases (3 Crohn's disease, 2 ulcerative colitis) refractory to systemic steroid treatment and 5 cases of Crohn's disease with fistula. Patients received an intravenous infusion of infliximab at 3-5 mg/kg body weight.
  
  
  RESULTS
  In 3 cases of refractory Crohn's patients, clinical response and remission induction were obtained in 2 (67%) and 1 cases (33%). After infusion of infliximab, the occlusion of internal fistula could be found in all 2 cases. Two out of 3 cases of anal fistula were completely healed. In two cases of refractory ulcerative colitis, one case who showed clinical manifestation of toxic megacolon had improved and avoided the colectomy, but the other case did not respond to the infusion of infliximab and underwent colon resection.
  
  
  CONCLUSIONS
  We found that administration of infliximab is an effective alternative for refractory and fistulizing Crohn's disease but further studies are necessary for refractory ulcerative colitis.
authors.affiliation: Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.
authors.forename: Ki Myung
authors.initials: KM
authors.lastname: Lee
authors.forename: Jong Soo
authors.initials: JS
authors.lastname: Kim
authors.forename: Do Hyun
authors.initials: DH
authors.lastname: Shin
authors.forename: Jae Youn
authors.initials: JY
authors.lastname: Cheong
authors.forename: Byung Moo
authors.initials: BM
authors.lastname: Yoo
authors.forename: Jai Keun
authors.initials: JK
authors.lastname: Kim
authors.forename: Kwang Jae
authors.initials: KJ
authors.lastname: Lee
authors.forename: Ki Baik
authors.initials: KB
authors.lastname: Hahm
authors.forename: Jin Hong
authors.initials: JH
authors.lastname: Kim
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Cho
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000150:complications; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab